Together with scRNA-seq data of recurrent GBM tissues from patients receiving versus not receiving ICI, our study shows the potential incorporation of CD69 immuno-PET as a response assessment to immunotherapy in patients with GBM. The gene discussed is CD69; the disease is glioblastoma.